These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 25355696)

  • 1. Nanoparticles: take only pictures, leave only footprints.
    Choyke PL
    Sci Transl Med; 2014 Oct; 6(260):260fs44. PubMed ID: 25355696
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bladder cancer: On the dot--targeted molecular imaging.
    Stone L
    Nat Rev Urol; 2015 Jan; 12(1):6. PubMed ID: 25403247
    [No Abstract]   [Full Text] [Related]  

  • 3. Endoscopic molecular imaging of human bladder cancer using a CD47 antibody.
    Pan Y; Volkmer JP; Mach KE; Rouse RV; Liu JJ; Sahoo D; Chang TC; Metzner TJ; Kang L; van de Rijn M; Skinner EC; Gambhir SS; Weissman IL; Liao JC
    Sci Transl Med; 2014 Oct; 6(260):260ra148. PubMed ID: 25355698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Re: Endoscopic Molecular Imaging of Human Bladder Cancer Using a CD47 Antibody.
    Chang SS
    J Urol; 2016 Apr; 195(4 Pt 1):1170. PubMed ID: 27302826
    [No Abstract]   [Full Text] [Related]  

  • 5. Surface-Enhanced Raman Scattering Nanoparticles for Multiplexed Imaging of Bladder Cancer Tissue Permeability and Molecular Phenotype.
    Davis RM; Kiss B; Trivedi DR; Metzner TJ; Liao JC; Gambhir SS
    ACS Nano; 2018 Oct; 12(10):9669-9679. PubMed ID: 30203645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Functional imaging in bladder cancer].
    Maurer T; Horn T; Beer AJ; Eiber M; Gschwend JE
    Urologe A; 2013 Apr; 52(4):509-14. PubMed ID: 23483270
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Positron emission tomography-computerized tomography findings in a urinary bladder paraganglioma.
    Thambugala GM; Fulham MJ; Mohamed A
    Australas Radiol; 2007 Oct; 51 Spec No.():B45-7. PubMed ID: 17875156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Replication Study: The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors.
    Horrigan SK;
    Elife; 2017 Jan; 6():. PubMed ID: 28100392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fluorodeoxyglucose positron-emission tomography (FDG PET)/computed tomography (CT) in bladder cancer.
    Goh V; Cook G
    BJU Int; 2013 Oct; 112(6):709. PubMed ID: 24028759
    [No Abstract]   [Full Text] [Related]  

  • 10. [Comment on the article "New cryotherapy probe with exchangeable optics for transurethral treatment of bladder tumors"by L. Steffens and W. Vahlensieck (this J. 13, 119-121 (1974)) and discussion (this J. 13, 202 (1974))].
    Molnár S
    Urologe A; 1975 Jan; 14(1):48. PubMed ID: 1114525
    [No Abstract]   [Full Text] [Related]  

  • 11. CD47 blockade as another immune checkpoint therapy for cancer.
    Vonderheide RH
    Nat Med; 2015 Oct; 21(10):1122-3. PubMed ID: 26444633
    [No Abstract]   [Full Text] [Related]  

  • 12. Stealth functionalization of biomaterials and nanoparticles by CD47 mimicry.
    Gheibi Hayat SM; Bianconi V; Pirro M; Sahebkar A
    Int J Pharm; 2019 Oct; 569():118628. PubMed ID: 31421198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. On the mechanism of CD47 targeting in cancer.
    Zhao XW; Matlung HL; Kuijpers TW; van den Berg TK
    Proc Natl Acad Sci U S A; 2012 Oct; 109(42):E2843; author reply E2844-5. PubMed ID: 22923695
    [No Abstract]   [Full Text] [Related]  

  • 14. Targeting CD47 in Anaplastic Thyroid Carcinoma Enhances Tumor Phagocytosis by Macrophages and Is a Promising Therapeutic Strategy.
    Schürch CM; Roelli MA; Forster S; Wasmer MH; Brühl F; Maire RS; Di Pancrazio S; Ruepp MD; Giger R; Perren A; Schmitt AM; Krebs P; Charles RP; Dettmer MS
    Thyroid; 2019 Jul; 29(7):979-992. PubMed ID: 30938231
    [No Abstract]   [Full Text] [Related]  

  • 15. [Conclusion to the comment by S. Molnár].
    Steffens L; Vahlensieck W
    Urologe A; 1975 Jan; 14(1):49. PubMed ID: 1114526
    [No Abstract]   [Full Text] [Related]  

  • 16. The identification of a CD47-blocking "hotspot" and design of a CD47/PD-L1 dual-specific antibody with limited hemagglutination.
    Shi R; Chai Y; Duan X; Bi X; Huang Q; Wang Q; Tan S; Gao GF; Zhu J; Yan J
    Signal Transduct Target Ther; 2020 Mar; 5(1):16. PubMed ID: 32296041
    [No Abstract]   [Full Text] [Related]  

  • 17. Imaging of bladder cancer: update on current approaches for diagnosis.
    Turkbey B; Turkbey EB; Ravizzini G; Karcaaltincaba M
    JBR-BTR; 2011; 94(4):178-84. PubMed ID: 21980733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of (18) F-fluorodeoxyglucose (FDG)-positron-emission tomography/computed tomography (PET/CT) on management of patients with carcinoma invading bladder muscle.
    Mertens LS; Fioole-Bruining A; Vegt E; Vogel WV; van Rhijn BW; Horenblas S
    BJU Int; 2013 Oct; 112(6):729-34. PubMed ID: 23790129
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Technologic developments in the field of photonics for the detection of urinary bladder cancer.
    Palmer S; Sokolovski SG; Rafailov E; Nabi G
    Clin Genitourin Cancer; 2013 Dec; 11(4):390-6. PubMed ID: 23871799
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of CD47-SIRPα immune checkpoint in tumor immune evasion and innate immunotherapy.
    Li Z; Li Y; Gao J; Fu Y; Hua P; Jing Y; Cai M; Wang H; Tong T
    Life Sci; 2021 May; 273():119150. PubMed ID: 33662426
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.